Clinical observations show that several syndromes have high risk inducing CHF, such as hypertension (He et al., 2001), age factors (Fukuta and Little, 2007) and neurohormonal system disorder (Landmesser et al., 2009), etc. Common used therapies for CHF include angiotensin converting enzyme inhibitors (Berliner and Bauersachs, 2017), beta-receptor blockers (Oniorisan and Lanfear, 2014), mineralocorticoid receptor antagonist (Liu et al., 2015), diuretics (Faris et al., 2012) and other modern medicines. Here, NR3C2 is linked to congestive heart failure.